Attached files
| file | filename |
|---|---|
| EX-32.2 - MyMD Pharmaceuticals, Inc. | ex32-2.htm |
| EX-31.2 - MyMD Pharmaceuticals, Inc. | ex31-2.htm |
| EX-31.1 - MyMD Pharmaceuticals, Inc. | ex31-1.htm |
| EX-23.1 - MyMD Pharmaceuticals, Inc. | ex23-1.htm |
| EX-21.1 - MyMD Pharmaceuticals, Inc. | ex21-1.htm |
| EX-4.1 - MyMD Pharmaceuticals, Inc. | ex4-1.htm |
| 10-K - MyMD Pharmaceuticals, Inc. | form10-k.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Annual Report on Form 10-K of Akers Biosciences, Inc. (the “Company”) for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, the undersigned, Christopher C. Schreiber, as the President and Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: March 1, 2021 | By: | /s/ Christopher C. Schreiber |
| Christopher
C. Schreiber, President and Chief Executive Officer (Principal Executive Officer) |
The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-K or as a separate disclosure document.